Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRI management of NMOSD and MOGAD: Proposals from the French Expert Group NOMADMUS.
Durand-Dubief F, Shor N, Audoin B, Bourre B, Cohen M, Kremer S, Maillart E, Papeix C, Ruet A, Savatovsky J, Tourdias T, Ayrignac X, Ciron J, Collongues N, Laplaud D, Michel L, Deschamps R, Thouvenot E, Zephir H, Marignier R, Cotton F; NOMADMUS Study Group. Durand-Dubief F, et al. Among authors: papeix c. J Neuroradiol. 2024 Dec 1;52(1):101235. doi: 10.1016/j.neurad.2024.101235. Online ahead of print. J Neuroradiol. 2024. PMID: 39626832 Free article.
A benign form of neuromyelitis optica: does it exist?
Collongues N, Cabre P, Marignier R, Zéphir H, Papeix C, Audoin B, Lebrun-Frenay C, Pelletier J, Fontaine B, Vermersch P, Confavreux C, de Seze J; Group Members for NOMADMUS and CF-SEP. Collongues N, et al. Among authors: papeix c. Arch Neurol. 2011 Jul;68(7):918-24. doi: 10.1001/archneurol.2011.127. Arch Neurol. 2011. PMID: 21747032
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.
Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, Cavillon G, Rogemond V, Casey R, Frangoulis B, De Sèze J, Vukusic S, Honnorat J, Confavreux C; NOMADMUS Study Group. Marignier R, et al. Among authors: papeix c. Neurology. 2013 Jun 11;80(24):2194-200. doi: 10.1212/WNL.0b013e318296e917. Epub 2013 May 8. Neurology. 2013. PMID: 23658379
[New and emerging treatments for multiple sclerosis].
Louapre C, Maillart É, Papeix C, Lubetzki C. Louapre C, et al. Among authors: papeix c. Med Sci (Paris). 2013 Dec;29(12):1105-10. doi: 10.1051/medsci/20132912013. Epub 2013 Dec 20. Med Sci (Paris). 2013. PMID: 24356140 Free article. Review. French.
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators. Cohen M, et al. Among authors: papeix c. JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240. JAMA Neurol. 2014. PMID: 24566807 Clinical Trial.
Cavitary pulmonary disease in a patient treated with natalizumab.
de Masson A, Maillart E, Veziris N, Meyssonnier V, Papeix C, Caumes E. de Masson A, et al. Among authors: papeix c. Presse Med. 2014 Sep;43(9):1009-12. doi: 10.1016/j.lpm.2013.12.012. Epub 2014 Apr 16. Presse Med. 2014. PMID: 24742610 No abstract available.
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups. Barbin L, et al. Among authors: papeix c. Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29. Neurology. 2016. PMID: 26826205 Free PMC article.
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks. Pignolet B, et al. Among authors: papeix c. Neurology. 2016 Dec 6;87(23):2491-2494. doi: 10.1212/WNL.0000000000003401. Epub 2016 Nov 4. Neurology. 2016. PMID: 27815407 Clinical Trial. No abstract available.
183 results